SPRINT

Sprint Bioscience

Market Cap 148.5M

Sprint Bioscience grundades år 2009 av Prof. Pär Nordlund, Dr. Anders Åberg, Martin Andersson, Jessica Martinsson och Kenth Hallberg. Bolaget är ett bioteknikbolag med fokus på utveckling av nya och innovativa läkemedel inom cancer och diabetes. Forskningen är fokuserad till tre angränsande fält: tumörmetabolism, immunonkologi och tumörens mikromiljö. Bolaget har sedan det grundades framgångsrikt drivit två projekt fram till licensavtal med Bayer Pharmaceuticals och Petra Pharma Corporation.

+ more

Redeye Research

Reports

Notes

Today
Day High
15.05
14.7
Day Low
14.00
Day Open
14.90
Prev Close
14.70
VWAP
14.2
Volume
59K
Turnover
0.844M
Top Broker
VWAP
14.8
Avg Volume
54K
Avg Turnover
0.797M
Top Brokers
AVA/NON
VWAP
14.5
Avg Volume
41K
Avg Turnover
0.587M
Top Brokers
AVA/NON
VWAP
14.2
Avg Volume
27K
Avg Turnover
0.383M
Top Brokers
AVA/NON
52 week summary
Price Range
9.1
Last
30.6
Beta
N/A
Market Cap
148.5M
Total Return
-41.0%
Trailing P/E
-13.9
Div Yield
0.0%
Shares Outstanding
10.1M
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months 48.1%
Change 12 Months -40.9%
Volume Trend
Average Volume 10 vs 60 Days 89.1%
Price VS
52 Week High -52.0%
50 Day Moving Average 10.4%
200 Day moving Average 6.8%

Add article markers

Compare Sprint Bioscience to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2017-05-13 Source: Redeye
Major Owners Equity Votes
Första Entreprenörsfonden 23.1%
23.1%
Pär Nordlund 9.2%
9.2%
Håkan Roos 7.0%
7.0%
Kudu AB 4.4%
4.4%
ALMI 4.2%
4.2%
Jessica Martinsson 3.4%
3.4%
Martin Erik Andersson 3.4%
3.4%
Staffan Halldin 3.3%
3.3%
Wts Invest AB 3.0%
3.0%
Mikael Lönn 2.9%
2.9%
Last updated: 2018-04-17 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
20,000
0 Sales
0
Last 24 weeks
1 Purchases
20,000
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • -123.3%
  • -55.1%
  • -137.5%
  • -196.1%
  • -198.8%
  • -200.6%
  •  
  • -2.37
  • -2.37
  • 0.00
  •  
  • 6.5
  •  
  • 18.2
  • 0.0
  • 0.0
  • 0.0
  • 2.4
  • -1.2
  • -1.2
  • 0.0
  •  
  • 15.7%
  • 100.0%
  • 18
  • 23
  • 0.3
  • 2015
  •  
  •  
  • 8
  • 7
  • 0
  • 0
  • 15
  •  
  • 1
  • 0
  • 0
  • 0
  • 0
  • 15
  • 0
  • 16
  • 0
  • 31
  •  
  •  
  • 25
  • 0
  • 0
  • 25
  • 1
  • 0
  • 0
  • 26
  • 0
  • 0
  • 5
  • 0
  • 5
  • 31
  • 2015
  • 8
  • -23
  • 0
  • -15
  • 0
  • -15
  • 0
  • -15
  • -6
  • -6
  • -27
  • 2015 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2015 Q4
  • 8
  • -23
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • -15
  • 2016
  •  
  • 37.0%
  • 12.8%
  • 19.9%
  • 22.6%
  • 13.1%
  • 13.0%
  •  
  • 0.64
  • 0.64
  • 0.00
  •  
  • 7.1
  •  
  • -2.6
  • 0.0
  • 0.0
  • 0.0
  • -0.1
  • -0.3
  • -0.6
  • 0.0
  •  
  • 39.9%
  • 100.0%
  • -3
  • 17
  • 0.7
  • 2016
  •  
  •  
  • 24
  • 3
  • 0
  • 0
  • 27
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 21
  • 0
  • 23
  • 0
  • 50
  •  
  •  
  • 21
  • 0
  • 0
  • 21
  • 0
  • 0
  • 0
  • 21
  • 0
  • 9
  • 20
  • 0
  • 20
  • 50
  • 2016
  • 35
  • -27
  • -3
  • 5
  • 0
  • 5
  • 3
  • 8
  • 4
  • -10
  • 10
  • 2016 Q1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q3
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q4
  • 35
  • -27
  • 8
  • -3
  • 0
  • 0
  • 5
  • 0
  • 0
  • 0
  • 5
  • 0
  • 5
  • 2017
  •  
  • -69.6%
  • -36.1%
  • -62.1%
  • -42.2%
  • -44.5%
  • -44.6%
  •  
  • -1.06
  • -1.06
  • 0.00
  •  
  • 10.1
  •  
  • 5.9
  • 0.0
  • 0.0
  • 0.0
  • 0.2
  • -0.6
  • -0.6
  • 0.0
  •  
  • 31.0%
  • 100.0%
  • 6
  • 17
  • 0.7
  • 2017
  •  
  •  
  • 1
  • 3
  • 0
  • 0
  • 5
  •  
  • 2
  • 0
  • 0
  • 0
  • 0
  • 29
  • 0
  • 31
  • 0
  • 35
  •  
  •  
  • 7
  • 0
  • 0
  • 7
  • 0
  • 0
  • 0
  • 7
  • 0
  • 17
  • 11
  • 0
  • 11
  • 35
  • 2017
  • 24
  • -34
  • -1
  • -11
  • 0
  • -11
  • 1
  • -10
  • 0
  • -9
  • -10
  • 2017 Q1
  • 9
  • -8
  • 1
  • 0
  • 0
  • 0
  • 1
  • 0
  • 0
  • 0
  • 1
  • 0
  • 1
  • 2017 Q2
  • 9
  • -8
  • 1
  • 0
  • 0
  • 0
  • 1
  • 0
  • 0
  • 0
  • 1
  • 0
  • 1
  • 2017 Q3
  • 2
  • -8
  • -5
  • 0
  • 0
  • 0
  • -6
  • 0
  • 0
  • 0
  • -6
  • 0
  • -6
  • 2017 Q4
  • 3
  • -10
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • -7
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E
  • 2020 Q2 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-04-17 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.